Cosmo Pharmaceuticals Statistics

Total Valuation

Cosmo Pharmaceuticals has a market cap or net worth of CHF 1.20 billion. The enterprise value is 1.08 billion.

Market Cap	1.20B
Enterprise Value	1.08B

Important Dates

The next estimated earnings date is Thursday, October 24, 2024.

Earnings Date	Oct 24, 2024
Ex-Dividend Date	Jul 10, 2024

Share Statistics

Cosmo Pharmaceuticals has 16.05 million shares outstanding. The number of shares has decreased by -0.77% in one year.

Shares Outstanding	16.05M
Shares Change (YoY)	-0.77%
Shares Change (QoQ)	+0.54%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	15.93%
Float	8.42M

Valuation Ratios

The trailing PE ratio is 17.96 and the forward PE ratio is 11.53.

PE Ratio	17.96
Forward PE	11.53
PS Ratio	6.73
PB Ratio	2.50
P/FCF Ratio	10.92
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.13, with an EV/FCF ratio of 9.82.

EV / Earnings	16.10
EV / Sales	6.04
EV / EBITDA	11.13
EV / EBIT	13.03
EV / FCF	9.82

Financial Position

The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.00.

Current Ratio	4.85
Quick Ratio	4.35
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	21.40

Financial Efficiency

Return on equity (ROE) is 14.80% and return on invested capital (ROIC) is 9.59%.

Return on Equity (ROE)	14.80%
Return on Assets (ROA)	7.82%
Return on Capital (ROIC)	9.59%
Revenue Per Employee	526,444
Profits Per Employee	197,600
Employee Count	325
Asset Turnover	0.27
Inventory Turnover	3.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +100.80% in the last 52 weeks. The beta is 1.25, so Cosmo Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.25
52-Week Price Change	+100.80%
50-Day Moving Average	77.04
200-Day Moving Average	69.72
Relative Strength Index (RSI)	42.66
Average Volume (20 Days)	16,683

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cosmo Pharmaceuticals had revenue of CHF 178.46 million and earned 66.99 million in profits. Earnings per share was 4.16.

Revenue	178.46M
Gross Profit	136.47M
Operating Income	82.78M
Pretax Income	83.39M
Net Income	66.99M
EBITDA	96.20M
EBIT	82.78M
Earnings Per Share (EPS)	4.16

Full Income Statement

Balance Sheet

The company has 128.45 million in cash and 1.40 million in debt, giving a net cash position of 127.05 million or 7.92 per share.

Cash & Cash Equivalents	128.45M
Total Debt	1.40M
Net Cash	127.05M
Net Cash Per Share	7.92
Equity (Book Value)	486.60M
Book Value Per Share	29.91
Working Capital	140.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 112.96 million and capital expenditures -3.21 million, giving a free cash flow of 109.75 million.

Operating Cash Flow	112.96M
Capital Expenditures	-3.21M
Free Cash Flow	109.75M
FCF Per Share	6.84

Full Cash Flow Statement

Margins

Gross margin is 76.47%, with operating and profit margins of 46.38% and 37.53%.

Gross Margin	76.47%
Operating Margin	46.38%
Pretax Margin	46.72%
Profit Margin	37.53%
EBITDA Margin	53.90%
EBIT Margin	46.38%
FCF Margin	61.50%

Dividends & Yields

This stock pays an annual dividend of 1.88, which amounts to a dividend yield of 2.51%.

Dividend Per Share	1.88
Dividend Yield	2.51%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	6.07%
Buyback Yield	0.77%
Shareholder Yield	3.29%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cosmo Pharmaceuticals has an Altman Z-Score of 5.97.

Altman Z-Score	5.97
Piotroski F-Score	n/a